RIPRETINIB vs RISANKIZUMAB: Which Drug Is Safer?
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
RIPRETINIB vs RISANKIZUMAB: Safety Overview
| Metric | RIPRETINIB | RISANKIZUMAB |
|---|---|---|
| Total FAERS Reports | 4,432 | 2,642 |
| Deaths Reported | 465 | 41 |
| Death Rate | 10.5% | 1.6% |
| Hospitalizations | 948 | 439 |
| Average Patient Age | 66.8 yrs | 52.1 yrs |
| % Female Patients | 45.3% | 51.3% |
| FDA Approval Date | May 15, 2020 | N/A |
| Manufacturer | Deciphera Pharmaceuticals, LLC | AbbVie Inc. |
| Route | ORAL | SUBCUTANEOUS |
| Marketing Status | Prescription | N/A |